Fifth Third Bancorp Grows Stock Holdings in Biogen Inc. $BIIB

Fifth Third Bancorp lifted its position in Biogen Inc. (NASDAQ:BIIB) by 255.1% in the first quarter, Holdings Channel.com reports. The firm owned 32,716 shares of the biotechnology company’s stock after purchasing an additional 23,504 shares during the quarter. Fifth Third Bancorp’s holdings in Biogen were worth $5,998,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Reflection Asset Management purchased a new stake in Biogen in the fourth quarter worth approximately $25,000. WPG Advisers LLC raised its stake in shares of Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares in the last quarter. First Horizon Corp purchased a new position in shares of Biogen during the fourth quarter worth approximately $30,000. WFA of San Diego LLC bought a new stake in shares of Biogen in the 2nd quarter worth approximately $32,000. Finally, Root Financial Partners LLC lifted its holdings in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen Stock Up 5.9%

Shares of Biogen stock opened at $208.92 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $219.72. The company’s 50 day moving average price is $199.18 and its 200-day moving average price is $188.88. The stock has a market capitalization of $30.84 billion, a price-to-earnings ratio of 22.42 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts forecast that Biogen Inc. will post 13.5 EPS for the current year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Synapticure launched a new virtual ataxia care program with Biogen support, highlighting continued investment in Biogen’s neurology franchise and potentially broadening patient access. Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
• Positive Sentiment: Biogen appointed Michael J. Parini as Chief Legal Officer, a seasoned biopharma leader whose compliance and strategic experience may support execution and governance. Biogen Appoints Michael J. Parini as Chief Legal Officer
• Neutral Sentiment: Analysts offered fresh commentary on Biogen, but the headline did not include a clear new rating or target change, so the stock impact appears limited. Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Biogen (BIIB)
• Negative Sentiment: Recent Alzheimer’s-related data on diranersen and tau-targeting ASO programs raised questions about dosing and trial progress, which weighed on sentiment toward Biogen’s pipeline. Biogen shares slide as diranersen data raise dosing question
• Negative Sentiment: Investors reacted negatively to detailed diranersen Alzheimer’s study data, as the results reinforced concerns about a prior phase II setback despite plans to move ahead. Biogen Shares Decline After Detailed Diranersen Alzheimer’s Study Data

Wall Street Analyst Weigh In

Several research firms recently commented on BIIB. Canaccord Genuity Group increased their target price on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Royal Bank Of Canada boosted their price target on shares of Biogen from $227.00 to $242.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. The Goldman Sachs Group upped their price target on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Truist Financial raised Biogen from a “hold” rating to a “buy” rating and raised their price objective for the company from $190.00 to $235.00 in a research note on Monday. Finally, Mizuho decreased their price objective on Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and a consensus price target of $220.04.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.